{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:34Z","timestamp":1787013934546,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T00:00:00Z","timestamp":1428451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Splenic marginal zone lymphoma (\n                    <jats:styled-content style=\"fixed-case\">SMZL<\/jats:styled-content>\n                    ) accounts for less than 2% of all non\u2010Hodgkin lymphomas. We identified 107 cases diagnosed with\n                    <jats:styled-content style=\"fixed-case\">SMZL<\/jats:styled-content>\n                    between 1985 and 2012 from the British Columbia Cancer Agency Centre for Lymphoid Cancer and Lymphoma Pathology Databases. Patient characteristics were: median age 67\u00a0years (range 30\u201388), male 40%, stage\n                    <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>\n                    98%, splenomegaly 93%, bone marrow involvement 96%, peripheral blood involvement 87%. As initial treatment, 52 underwent splenectomy (10 with chemotherapy), 38 chemotherapy alone (21 chemoimmunotherapy containing rituximab, 1 rituximab alone), two antivirals for hepatitis C, and 15 were only observed. The 10\u2010year overall survival for first\u2010line splenectomy versus chemotherapy was 61% and 42%, respectively [Hazard Ratio (\n                    <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                    ) 0\u00b748, 95% confidence interval (\n                    <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                    ) 0\u00b726\u20130\u00b788,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b7017]. The 10\u2010year failure\u2010free survival (\n                    <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>\n                    ) after first\u2010line splenectomy vs chemotherapy was 39% and 14%, respectively (\n                    <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                    0\u00b748, 95%\n                    <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                    0\u00b728\u20130\u00b780,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b7004). Among the 38 patients who received first\u2010line chemotherapy,\n                    <jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>\n                    was similar between those receiving rituximab (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a022) and those who did not (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a016) (\n                    <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                    0\u00b764, 95%\n                    <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                    0\u00b731\u20131\u00b734,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b7238). Fifteen patients transformed to aggressive lymphoma with median time to transformation of 3\u00b75\u00a0years (range 6\u00a0months to 12\u00a0years) and the 10\u2010year transformation rate was 18%. In conclusion, splenectomy remains a reasonable treatment for patients with\n                    <jats:styled-content style=\"fixed-case\">SMZL<\/jats:styled-content>\n                    .\n                  <\/jats:p>","DOI":"10.1111\/bjh.13320","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T20:55:03Z","timestamp":1428526503000},"page":"520-527","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia"],"prefix":"10.1111","volume":"169","author":[{"given":"Katharine H.","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Medical Oncology British Columbia Cancer Agency \u2013 Vancouver Island Centre Victoria BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit","family":"Kahlon","sequence":"additional","affiliation":[{"name":"Department of Hematology Surrey Memorial Hospital Surrey BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Skinnider","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Pathology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Pathology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham W.","family":"Slack","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Pathology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara N.","family":"Shenkier","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Klasa","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology British Columbia Cancer Agency Vancouver BC Canada"},{"name":"Leukemia\/BMT Program of British Columbia Vancouver General Hospital Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4659"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.004"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.844"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.1950"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt181"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12036"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013376"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20596"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.845884"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.861067"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.6.1558.1558"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405068"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12011"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb04417.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04165.x"},{"key":"e_1_2_7_21_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00981-1"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21931"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13320","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T22:35:57Z","timestamp":1696286157000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/bjh.13320"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13320","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,8]]},"assertion":[{"value":"2014-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}